Virtual Library
Start Your Search
H. Adachi
Author of
-
+
P2.07 - Poster Session 2 - Surgery (ID 190)
- Event: WCLC 2013
- Type: Poster Session
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.07-010 - surgical treatment and outcome of multiple primary lung cancers (ID 1153)
09:30 - 09:30 | Author(s): H. Adachi
- Abstract
Background
Recently, multiple primary lung cancer is inreasing with progress of imaging diagnostic technology and improvement in treatment results. We assesed the selection of the type of pulmonary resection, operative morbidity, mortality and the outcome of our cases which enforced surgical treatment for multiple primary lung cancer.Methods
Of 840 patients who underwent operation for primary lung cancer between January 2001 and May 2013.We consider 57(6.7%) to have a multiple primary lung cancer. We use the criteria of Martini and Melamed as a diagnosis of multiple primary lung cancer.Results
The group comprised 27 men and 30 women. Median age was 66.7 years (48-80). It occured synchronous in 21 cases and metachronous in 36 cases. Cell type combination was adenocarcinoma-adenocarcinoma in 37 cases, adenocarcinoma-squamous cell carcinoma in 10 cases, squamous cell carcinoma-squamous cell carcinoma in 6 cases, adenocarcinoma-large cell carcinoma in 3 cases and large cell carcinoma-large cell carcinoma in 1 case. Operative procedures was lobectomy-lobectomy in 13 cases, lobectomy-segmentectomy in 12 cases, lobectomy-edge resectionin 19 cases, edge resection-edge resection in 5 cases and lobectomy/edge resection-radio therapy in 3 cases. Pathological stage for the first cancer was IA/IB/IIA/IIB/III = 35/14/4/0/4. The 5 year survival rate after first surgery was 81.7%, and second surgery was 72.2%.Conclusion
With this result, we consider that surgical resection may prove beneficial in cases which postoperative good survival can be expected by the aggressive surgical approach, despite it is difficult to distinguish multiple primary lung cancers and metastatic cancers preoperatively.